GlassScriptPhysician profile
Marlene B Kremer
NPI 1831205749
$5,393.55
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2020: $711 · 2021: $674 · 2022: $1,094 · 2023: $1,645 · 2024: $14.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,659.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $900.11 | 2019-2023 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $755.31 | 2019-2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $611.49 | 2020-2023 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $507.72 | 2019-2023 | |
| Lilly USA, LLC | $457.60 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.95 | 2019-2023 | Jardiance, Synjardy, Spiriva Respimat |
| Amgen INC. | $183.05 | 2019-2023 | Repatha, Otezla, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.69 | 2019-2024 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $155.50 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $138.44 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $130.77 | 2019-2023 | Yupelri |
| Pfizer INC. | $127.88 | 2019-2023 | |
| Dexcom, INC. | $123.84 | 2021-2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $111.61 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $86.67 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $56.79 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $56.70 | 2021-2023 | Eliquis |
| Astellas Pharma US INC | $54.32 | 2019-2020 | |
| Allergan, INC. | $53.15 | 2020 | |
| Merck Sharp & Dohme LLC | $52.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.51 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $40.88 | 2022-2023 | |
| Amarin Pharma, INC. | $36.74 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $35.18 | 2023 | Rexulti |
| Avanir Pharmaceuticals, INC. | $28.17 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.88 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.08 | 2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $16.39 | 2020 | |
| Sunovion Pharmaceuticals INC. | $15.51 | 2022 | |
| Horizon Therapeutics Plc | $13.38 | 2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $12.69 | 2023 | Quviviq |
| Exeltis, USA INC. | $12.53 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.79 | 2020 | |
| Eisai INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlene Kremer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.